De-nest and present filled glass vials and prefilled syringes for inspection/transfer in fill-finish
In aseptic fill-finish, sterile drug product is filled into thin-walled glass vials and prefilled syringes that arrive and move in nested trays. A robot must lift each fragile container out of tight nest pockets, present it for visual/automated inspection, and re-seat or transfer it without chipping, scratching, or cracking the glass or generating particulates. The objects are small, smooth, sometimes wet/cold, of variable fill weight, and frangible; they sit in the final, highest-value step of biologics production where each unit can hold high-cost biologic. The task is hard because grip force must be tightly modulated per container, slip must be sensed and corrected, and any glass-to-glass or glass-to-tooling contact must be detected before damage. AbbVie's explicit aseptic vial-and-syringe fill-finish business and its new small-volume-parenteral capacity make this a live operational area. We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionIn aseptic fill-finish, sterile drug product is filled into thin-walled glass vials and prefilled syringes that arrive and move in nested trays. A robot must lift each fragile container out of tight nest pockets, present it for visual/automated inspection, and re-seat or transfer it without chipping, scratching, or cracking the glass or generating particulates. The objects are small, smooth, sometimes wet/cold, of variable fill weight, and frangible; they sit in the final, highest-value step of biologics production where each unit can hold high-cost biologic. The task is hard because grip force must be tightly modulated per container, slip must be sensed and corrected, and any glass-to-glass or glass-to-tooling contact must be detected before damage. AbbVie's explicit aseptic vial-and-syringe fill-finish business and its new small-volume-parenteral capacity make this a live operational area.
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.